OraSure Technologies (NASDAQ:OSUR) CEO Manner Carrie Eglinton Purchases 32,300 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton bought 32,300 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was bought at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the acquisition, the chief executive officer owned 2,190,874 shares of the company’s stock, valued at approximately $6,419,260.82. This trade represents a 1.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Manner Carrie Eglinton also recently made the following trade(s):

• On Friday, March 13th, Manner Carrie Eglinton acquired 22,022 shares of OraSure Technologies stock. The stock was purchased at an average price of $3.00 per share, for a total transaction of $66,066.00.

OraSure Technologies Stock Performance

Shares of OSUR opened at $3.08 on Tuesday. The stock has a market capitalization of $212.91 million, a P/E ratio of -3.31 and a beta of 0.88. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $4.22. The company’s fifty day moving average is $2.86 and its two-hundred day moving average is $2.78.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to analyst estimates of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%. Sell-side analysts predict that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

Institutional Investors Weigh In On OraSure Technologies

Institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. purchased a new position in shares of OraSure Technologies in the 2nd quarter valued at about $31,000. Quadrature Capital Ltd purchased a new stake in OraSure Technologies during the fourth quarter worth about $28,000. L2 Asset Management LLC acquired a new position in OraSure Technologies during the second quarter worth about $39,000. Coldstream Capital Management Inc. grew its position in OraSure Technologies by 128.2% during the second quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 7,477 shares during the period. Finally, Amundi purchased a new position in OraSure Technologies in the first quarter valued at about $47,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.